European Union suspends GVK Biosciences' generic drugs

Published: 3-Aug-2015
Regulatory Pharmaceutical

Indian company found to be manipulating data


European Union countries have until 20 August to suspend the sale of 700 generic drugs made by Indian company GVK Biosciences (GVK Bio), after the firm was found to be manipulating data, the European Commission said.

The firm was hired by drug companies to test whether the impact of generic versions of drugs was equal to the original, but investigations last year showed irregularities in all nine trials inspected.

The European Medicines Agency (EMA) said the problems, 'which stretched back years, highlight critical deficiencies in the quality system in place' at the company.

Specifically, GVK Bio had been manipulating electrocardiograms (ECGs) at its site in Hyderabad, according to Francois Herbert, Deputy Head of France’s National Agency for Medicines and Health Products Safety (ANSM), which carried out the inspections.

But the Commission said there is no reason to believe the drugs, including common pain reliever ibuprofen, had caused any health issues. A few have been re-authorised based on data from other labs.

The EMA recommended suspension in May this year, but several European countries, including France, Germany, Belgium and Luxembourg, had already begun blocking sales as early as December 2014.

  • Companies:
  • European Commission
  • GVK Biosciences Private Limited
See more

You may also like

Regulatory

How the EU's AI Act of 2024 will impact businesses using the technology

Read more
The legally binding rules on AI use aim to enhance the reliability and safety of the technology's implementation globally

Trending Articles

  1. IMed Consultancy helps Toby Orthopaedics navigate UK regulations Regulatory consultancy ensures compliance and confidence for Miami-based company
  2. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  3. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  4. Dual-chamber packaging systems as a simplification factor in the supply chain Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Regulatory

How the EU's AI Act of 2024 will impact businesses using the technology

The legally binding rules on AI use aim to enhance the reliability and safety of the technology's implementation globally
Regulatory

Timber Pharmaceuticals receives EC orphan drug designation

TMB-001 is a topical isotretinoin, formulated using the company’s patented IPEG delivery system
Regulatory

European Commission purchases additional Moderna vaccine doses

Under the terms of the agreement, the European Commission has the option to purchase an additional 150 million doses to be delivered in 2022
Regulatory

Tagrisso receives full approval in the EU

For patients with locally-advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer
Regulatory

Medicine and food authorities strongly recommend re-think of antimicrobials use in livestock

EMA and EFSA give joint opinion on EU measures to reduce antimicrobials use in food-producing animals
Ingredients

Pharma industry says EDC criteria need a risk-based approach

Strict, science-based guidelines will be implemented as soon as possible
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

EU considers endocrine disrupter controls

It has long been known that pharmaceutical residues can become hormone-affecting ‘endocrine disrupters’ when released into the environment and future controls are likely – but how will the legislators tackle the issue? Manufacturing Chemist reports
Subscribe now